OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopath
OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopathy. Note Omeros markets Yartemlea (narsoplimab), which is approved for hematopoietic stem cell transplant–associated thrombotic microangiopathy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.